• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023

    4/26/23 6:59:00 AM ET
    $NVTA
    Medical Specialities
    Health Care
    Get the next $NVTA alert in real time by email

    SAN FRANCISCO, April 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

    www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

    To access the conference call, please register at the link below:

    https://www.netroadshow.com/events/login?show=cd3e99e2&confId=49697

    Upon registering, each participant will be provided with call details and access codes. 

    The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website.

    About Invitae

    Invitae (NYSE:NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information simplified by digital technology. With accurate and actionable answers to strengthen medical decision-making, Invitae gives individuals and their families powerful, personalized insights that could improve and extend their lives. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.

    To learn more, visit invitae.com and follow for updates on Twitter, Instagram, Facebook and LinkedIn @Invitae.

    Invitae Contacts:

    Investor Relations

    Hoki Luk

    [email protected]

    Public Relations

    Amy Hadsock

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-to-announce-first-quarter-2023-financial-results-on-tuesday-may-9-2023-301807621.html

    SOURCE Invitae Corporation

    Get the next $NVTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVTA

    DatePrice TargetRatingAnalyst
    7/5/2023Underweight
    JP Morgan
    5/15/2023Mkt Perform → Underperform
    Raymond James
    1/31/2023$2.00Neutral → Sell
    Goldman
    8/25/2022$1.00Underperform
    Credit Suisse
    8/10/2022Neutral → Underweight
    JP Morgan
    7/26/2022$8.00 → $2.50Outperform → Market Perform
    Cowen
    7/21/2022Outperform → Mkt Perform
    Raymond James
    7/20/2022Buy → Neutral
    Ladenburg Thalmann
    More analyst ratings

    $NVTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Labcorp Announces Winning Bid for Select Assets of Invitae

      Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.

      4/24/24 9:27:00 PM ET
      $LH
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Enters into Agreement with Labcorp for Sale of Business

      – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis

      4/24/24 9:19:00 PM ET
      $LH
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Publishes its Environmental, Social and Governance (ESG) Report

      – Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring c

      4/22/24 12:43:00 PM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Invitae Corporation

      25-NSE - Invitae Corp (0001501134) (Subject)

      2/21/24 8:59:54 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Invitae Corp (0001501134) (Filer)

      2/14/24 6:59:56 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Invitae Corp (0001501134) (Filer)

      2/6/24 5:07:32 PM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Invitae

      JP Morgan resumed coverage of Invitae with a rating of Underweight

      7/5/23 7:28:43 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae downgraded by Raymond James

      Raymond James downgraded Invitae from Mkt Perform to Underperform

      5/15/23 7:28:13 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae downgraded by Goldman with a new price target

      Goldman downgraded Invitae from Neutral to Sell and set a new price target of $2.00

      1/31/23 6:15:23 AM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nussbaum Robert L covered exercise/tax liability with 17,404 shares, decreasing direct ownership by 3% to 551,941 units (SEC Form 4)

      4 - Invitae Corp (0001501134) (Issuer)

      12/21/23 9:20:16 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Brida Thomas covered exercise/tax liability with 17,404 shares, decreasing direct ownership by 2% to 916,183 units (SEC Form 4)

      4 - Invitae Corp (0001501134) (Issuer)

      12/21/23 9:14:33 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Sholehvar David was granted 850,000 shares (SEC Form 4)

      4 - Invitae Corp (0001501134) (Issuer)

      11/14/23 7:58:49 PM ET
      $NVTA
      Medical Specialities
      Health Care